# GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors

> **NCT03576131** · PHASE1,PHASE2 · TERMINATED · sponsor: **Genmab** · enrollment: 48 (actual)

## Conditions studied

- Colorectal Cancer
- Non-small Cell Lung Cancer
- Triple Negative Breast Cancer
- Renal Cell Carcinoma
- Gastric Cancer
- Pancreatic Cancer
- Urothelial Cancer

## Interventions

- **BIOLOGICAL:** GEN1029 (HexaBody®-DR5/DR5)

## Key facts

- **NCT ID:** NCT03576131
- **Lead sponsor:** Genmab
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-04-30
- **Primary completion:** 2021-10-12
- **Final completion:** 2021-10-12
- **Target enrollment:** 48 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2023-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03576131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03576131, "GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03576131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*